OBP-B inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the OBP-B protein, a member of the odorant-binding protein (OBP) family. These proteins are primarily involved in the detection and transport of odorant molecules, playing a crucial role in the olfactory system by binding to volatile compounds and facilitating their transport to olfactory receptors. OBP-B, like other members of the OBP family, possesses a hydrophobic binding pocket that allows it to interact with a wide range of small, hydrophobic molecules. Inhibitors of OBP-B are typically small molecules that bind to this hydrophobic pocket or other key regions of the protein, thereby blocking its ability to bind to odorants. This inhibition can alter the protein's function in the olfactory process, potentially disrupting the normal signaling pathways associated with scent detection.
The development of OBP-B inhibitors involves a comprehensive understanding of the protein's structure, particularly its binding pocket and the molecular interactions that facilitate odorant binding. Researchers often utilize high-throughput screening methods to identify initial lead compounds that can effectively bind to OBP-B and inhibit its function. These lead compounds are then subjected to structure-activity relationship (SAR) studies, where their chemical structures are refined to enhance binding affinity, selectivity, and stability within the OBP-B binding pocket. The chemical structures of OBP-B inhibitors are diverse, often featuring functional groups that enable strong interactions with the protein, such as hydrophobic contacts, hydrogen bonding, and van der Waals forces. Advanced structural biology techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to visualize these interactions at an atomic level, providing detailed insights that guide the design and optimization of these inhibitors. Achieving high selectivity is a key objective in the development of OBP-B inhibitors, ensuring that these compounds specifically target OBP-B without affecting other members of the OBP family or unrelated proteins. This selectivity is crucial for enabling precise modulation of OBP-B activity, allowing researchers to explore its specific role in the olfactory system and its broader implications in the molecular mechanisms of scent detection.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor, can disrupt multiple signaling pathways potentially linked to OBP-B. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor, could impact cell survival and proliferation pathways associated with OBP-B. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, potentially affecting pathways related to cell growth that might be regulated by OBP-B. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor, can affect gene expression, possibly influencing OBP-B activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor, may disrupt signaling cascades relevant to OBP-B function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, could alter MAPK/ERK pathway, indirectly affecting OBP-B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Also a MEK inhibitor, could impact MAPK signaling linked with OBP-B. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
p38 MAPK inhibitor, potentially disrupting stress response pathways associated with OBP-B. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, might impact cellular stress responses and apoptosis, related to OBP-B. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor, could influence protein degradation pathways involving OBP-B. | ||||||